3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents

被引:13
|
作者
Saqib, U. [1 ]
Siddiqi, M. I. [1 ]
机构
[1] Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India
关键词
type 2 diabetes mellitus; triazolopiperazine amide; 3D-QSAR; CoMFA; CoMSIA; dipeptidyl peptidase-IV; IMPROVED GLUCOSE-TOLERANCE; MOLECULAR-FIELD ANALYSIS; GLUCAGON-LIKE PEPTIDE-1; PARTIAL LEAST-SQUARES; FATTY RATS; POTENT; POLYPEPTIDE; THIAZOLIDIDE; VALIDATION; GLP-1;
D O I
10.1080/10629360903278677
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses were carried out on 45 triazolopiperazine amide derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors in order to elucidate their antidiabetic activities. The studies include Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). Models with good predictive abilities were generated with the cross-validated r2 ([image omitted]) and conventional r2 values of 0.589 and 0.868 for CoMFA and 0.586 and 0.868 for CoMSIA, respectively. Both models were validated by a test set of nine compounds and gave satisfactory predictive r2 ([image omitted]) values of 0.816 and 0.863, respectively. CoMFA and CoMSIA contour maps were then used to analyse the structural features of the ligands to account for the activity in terms of positively contributing physicochemical properties: steric, electrostatic, hydrophobic and hydrogen bond acceptor fields. The information obtained from CoMFA and CoMSIA three-dimensional contour maps can be used for further design of triazolopiperazine amide-based analogues as anti-diabetic agents.
引用
收藏
页码:519 / 535
页数:17
相关论文
共 50 条
  • [31] 3D-QSAR Studies of NAIMS Analogs as anti-HIV Agents
    Ganguly, S.
    Prasanthi, N.
    JOURNAL OF YOUNG PHARMACISTS, 2009, 1 (03) : 251 - 258
  • [32] 3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors
    Chakraborti, AK
    Gopalakrishnan, B
    Sobhia, ME
    Malde, A
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (08) : 1403 - 1408
  • [33] 3D-QSAR and docking studies of arylmethylamine-based DPP IV inhibitors
    Jiang, Chaoyi
    Han, Shuang
    Chen, Tiegang
    Chen, Jianzhong
    ACTA PHARMACEUTICA SINICA B, 2012, 2 (04) : 411 - 420
  • [34] QSAR and 3D-QSAR Models in the Field of Tubulin Inhibitors as Anticancer Agents
    Marzaro, Giovanni
    Chilin, Adriana
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (20) : 2253 - 2262
  • [35] In-Vitro Studies on Selected Jordanian Plants as Dipeptidyl Peptidase-IV Inhibitors for Management of Diabetes Mellitus
    Sewidan, Nuha
    Khalaf, Reema Abu
    Mohammad, Hani
    Hammad, Wa'ed
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (04): : 95 - 102
  • [36] Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice
    Matsuyama-Yokono, Akiko
    Tahara, Atsuo
    Nakano, Ryosuke
    Someya, Yuka
    Shiraki, Katsuhisa
    Hayakawa, Masahiko
    Shibasaki, Masayuki
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2009, 58 (03): : 379 - 386
  • [37] Design of anti-fungal agents by 3D-QSAR
    Sonak, Shreya S.
    Pathare, Sandeep
    Modi, Siddharth J.
    Kulkarni, Vithal M.
    INDIAN JOURNAL OF CHEMISTRY, 2022, 61 (07): : 744 - 754
  • [38] Anti-diabetic potential of Urena lobata leaf extract through inhibition of dipeptidyl peptidase IV activity
    Yudi Purnomo
    Djoko Wahono Soeatmadji
    Sutiman Bambang Sumitro
    Mochammad Aris Widodo
    Asian Pacific Journal of Tropical Biomedicine, 2015, (08) : 630 - 634
  • [39] Combination of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin with Other Anti-Diabetic Agents in Rodent Models
    Thomas, Leo
    Klein, Thomas
    Mark, Michael
    DIABETES, 2011, 60 : A284 - A284
  • [40] Design, synthesis and anti-diabetic activity of piperazine sulphonamide derivatives as dipeptidyl peptidase-4 inhibitors
    Kalli, Swarna Bharathi
    Velmurugan, V.
    PHARMACIA, 2022, 69 (04) : 987 - 993